Dual antiplatelet agent

This page covers all Dual antiplatelet agent drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin), P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin), COX-1 (aspirin); P2Y12 receptor (ticagrelor).

Targets

P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin) · P2Y12 receptor (ticagrelor); cyclooxygenase (aspirin) · COX-1 (aspirin); P2Y12 receptor (ticagrelor) · COX-1 (aspirin); P2Y12 receptor (clopidogrel) · Cyclooxygenase-1 (COX-1) and P2Y12 receptor · PAR-1 (vorapaxar) and P2Y12 receptor (clopidogrel) · Cyclooxygenase (COX) and P2Y12 receptor · COX-1 (aspirin); P2Y12 receptor (clopidogrel/ticagrelor) · P2Y12 receptor (clopidogrel); cyclooxygenase (acetylsalicylic acid)

Marketed (12)

• clopidogrel napadisilate + aspirin · Seoul National University Hospital · Cardiovascular
  This combination of clopidogrel napadisilate and aspirin inhibits platelet aggregation through dual antiplatelet pathways to prevent thrombotic events.
• ticagrelor + ASA · Peking University Third Hospital · Cardiovascular
  Ticagrelor and aspirin work together to inhibit platelet aggregation through different pathways, reducing blood clot formation.
• Aspirin + Ticagrelor · The First Affiliated Hospital with Nanjing Medical University · Cardiovascular
  Aspirin and ticagrelor work together as dual antiplatelet agents to prevent blood clots by inhibiting platelet aggregation through different pathways.
• ASA plus Clopidogrel · Texas Cardiac Arrhythmia Research Foundation · Cardiovascular
  ASA and clopidogrel together inhibit platelet aggregation through different pathways to reduce thrombotic events.
• Acetylsalicylic Acid + clopidogrel · Hospital Universitari Vall d'Hebron Research Institute · Cardiovascular
  This combination inhibits platelet aggregation through two complementary pathways: acetylsalicylic acid irreversibly inhibits cyclooxygenase to block thromboxane A2 production, while clopidogrel blocks the P2Y12 adenosine diphosphate receptor.
• Vorapaxar and Clopidogrel · Inova Health Care Services · Cardiovascular
  Vorapaxar and clopidogrel work together as dual antiplatelet agents to prevent blood clots by blocking platelet activation and aggregation through different pathways.
• Active Comparator: Aspirin+Clopidogrel · Chinese Academy of Medical Sciences, Fuwai Hospital · Cardiovascular
  Aspirin and clopidogrel together inhibit platelet aggregation through different pathways to prevent thrombotic events.
• Clopidogrel+Aspirin · Seoul National University Hospital · Cardiovascular
  Clopidogrel and aspirin together inhibit platelet aggregation through complementary pathways to prevent blood clots.
• clopidogrel bisulfate + aspirin · Seoul National University Hospital · Cardiovascular
  Clopidogrel and aspirin together inhibit platelet aggregation through complementary pathways to prevent blood clots.
• Aspirin combined with clopidogrel · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Cardiovascular
  Aspirin and clopidogrel together inhibit platelet aggregation through different pathways to prevent blood clots.
• Aspirin and clopidogrel/Ticagrelor · Beijing Neurosurgical Institute · Cardiovascular
  This combination of aspirin and a P2Y12 inhibitor (clopidogrel or ticagrelor) prevents blood clots by inhibiting platelet aggregation through multiple pathways.
• Clopidogrel with aspirin · University of Florida · Cardiovascular
  Clopidogrel and aspirin together inhibit platelet aggregation through complementary pathways to prevent blood clots.

Phase 3 pipeline (2)

• Clopidogrel+acetylsalicylic acid · Rigshospitalet, Denmark · Cardiovascular
  This combination inhibits platelet aggregation through two complementary pathways: clopidogrel blocks ADP-mediated platelet activation while acetylsalicylic acid inhibits thromboxane A2 synthesis.
• Clopidogrel plus ASA · University of Athens · Cardiovascular
  Clopidogrel and aspirin together inhibit platelet aggregation through complementary pathways to prevent thrombotic events.